An open-label cocktail drug-drug interaction (DDI) clinical study to assess the effect of multiple oral dosing with leniolisib on the pharmacokinetics (PK) of caffeine, midazolam, rosuvastatin, furosemide, and metformin in healthy subjects
LE 5101
Phase 1 other active
Quick answer
An open-label cocktail drug-drug interaction (DDI) clinical study to assess the effect of multiple oral dosing with leniolisib on the pharmacokinetics (PK) of caffeine, midazolam, rosuvastatin, furosemide, and metformin in healthy subjects for Activated Phosphoinositide 3-Kinase Delta Syndrome is a Phase 1 program (other) at Pharming Technologies B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharming Technologies B.V.
- Indication
- Activated Phosphoinositide 3-Kinase Delta Syndrome
- Phase
- Phase 1
- Modality
- other
- Status
- active